

Astellas Establishes a new Affiliate In South East Europe

Tokyo, March 25, 2011, [Astellas Pharma Inc.](#) (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has established *Astellas Pharma d.o.o.* in Slovenia.

The regional management of Astellas’ South East European business will be located in Slovenia, and will be known as Astellas Pharma South East Europe. The details of the affiliate in which the regional management is based are as follows:

Name: *Astellas Pharma d.o.o.*
Established: December 2010
Location: Ljubljana, Slovenia
Representative: Mr. Adam Pearson, General Manager
Businesses description: Marketing and distribution of pharmaceuticals, etc.

Additionally, Astellas has established wholly-owned subsidiary (*Astellas d.o.o.*) in Croatia.

Astellas has already established wholly-owned subsidiaries in Romania and Bulgaria in August 2009. Astellas South East Europe will manage the business in Romania and Bulgaria, as well as Slovenia, Croatia, and some operations in Bosnia-Herzegovina, as one regional organisation.

Astellas Pharma South East Europe will play a key role in driving Astellas’ growth in South East European countries. The organisation will focus on marketing and selling Astellas’ portfolio of innovative global products including OMNIC[®] and OMNIC OCAS[®] for the treatment of the functional symptoms of benign prostatic hyperplasia, VESICARE[®] for the treatment of overactive bladder, PROTOPIC[®] for the treatment of atopic dermatitis and PROGRAF[®]/ ADVAGRAF[®], an immunosuppressant.

The establishment of Astellas Pharma South East Europe is an important step forwards in Astellas Pharma Europe’s ongoing programme of strategic geographical expansion and reflects the company’s commitment to introducing innovative and reliable pharmaceutical products that help to improve people’s lives around the world.

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas has approximately 16,000 employees worldwide. The organization is committed to becoming a global category leader in urology, immunology including transplantation and infectious diseases, oncology, neuroscience and DM complications and metabolic diseases. For more information on Astellas Pharma Inc., please visit our website at www.astellas.com/en/.

Contacts for inquiries or additional information

Astellas Pharma Inc.

Corporate Communications

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

<http://www.astellas.com>